The clinical manipulation of angiogenesis: Pathology, side-effects, surprises, and opportunities with novel human therapies

Journal of Pathology

Volumn 190, Issue 3, 2000, Pages 330-337

  Thompson, W Douglas ^a   Li, William W ^b,c,d   Maragoudakis, Michael ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b The Angiogenesis Foundation   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Manchester VA Medical Center   (United States)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Anti angiogenesis; Atherosclerosis; Cancer; Clinical trials; Side effects

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; BATIMASTAT; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; LEFLUNOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; PACLITAXEL; PENTOSAN POLYSULFATE; PRINOMASTAT; RAZOXANE; RECOMBINANT THROMBOCYTE FACTOR 4; SQUALAMINE; SURAMIN; TAMOXIFEN; TECOGALAN; THALIDOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER INHIBITION; CANCER THERAPY; DRUG INDUCED DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; FORECASTING; HUMANS; ISCHEMIA; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NERVOUS SYSTEM DISEASES; PROGNOSIS;

EID: 0034009936     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:3<330::AID-PATH588>3.0.CO;2-4     Document Type: Review

References (55)

1. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb. Lancet 1996; 348: 370-374.
2. Li WW, Li VW, Casey R. Arterial gene therapy. Lancet 1996; 348: 1381.
3. Ferrera N. VEGF and anti-VEGF: two sides of the same coin. In Angiogenesis Antagonists: Current trials, Drug Development, and Regulatory Issues. In press.
4. Langham M. Observations on the growth of blood vessels into the cornea. Application of a new experimental technique. Br J Ophthalmol 1953; 37: 210-222.
5. Schoefl GI, Majno G. Regeneration of blood vessels in wound healing. In Advances in Biology of Skin, vol V. Oxford: Pergamon Press, 1964; 173-193.
6. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. I. Comparison of experimental models of corneal vascularization. Am J Pathol 1975; 79: 537-554.
7. Ziehe M. The rat and rabbit cornea assay. In Angiogenesis: Models, Modulators and Clinical Applications, Maragoudakis M (ed). New York: Plenum Press, 1998; 39-46.
8. BenEzra D. Critical assessment of in vitro and in vivo assays of angiogenesis. In Angiogenesis: Models, Modulators and Clinical Applications, Maragoudakis M (ed). New York: Plenum Press, 1998; 85-89.
9. Li WW, Li VW, Casey R, et al. Clinical trials of angiogenesis-based therapies: overview and new guiding principles. In Angiogenesis: Models, Modulators and Clinical Applications, Maragoudakis M (ed). New York: Plenum Press, 1998; 475-492.
10. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991; 214: 414-427.
11. Robson MC. Exogenous growth factor application effect on human wound healing. Prog Dermatol 1996; 30: 1-7.
12. Steed DL, Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71-81.
13. Baumgartner L, Manor O, Blair R, Kearney M, Walsh K, Isner I. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischaemia. Circulation 1998; 97: 1114-1123.
14. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257: 1401-1403.
15. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischaemic porcine hearts. J Clin Invest 1994; 94: 623-630.
16. Lopez JJ, Simons M. Local extravascular growth factor delivery in myocardial ischaemia. Drug Delivery 1996; 3: 143-147.
17. Schumacher B, Pecher P, von Specht BU, Stegman TH. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-650.
18. Chen HH, Chien C-H, Liu HM. Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct. Stroke 1994; 25: 1651-1657.
19. Lin DA, Finkelstein SP. Basic fibroblast growth factor: a treatment for stroke. Neuroscientist 1997; 3: 247-250.
20. Kawamata T, Dietriech WD, Schallert T, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and upregulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci U S A 1997; 94: 8179-8184.
21. Soker S, Takashima S, Miao HO, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 739-745.
22. Engler CB, Sander B, Koefoed P, Larsen M, Vinding T, Lund-Anderson H. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. Acta Ophthalmol 1993; 71: 2731.
23. Ezekowitz RBA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992: 326: 1456-1463.
24. Schweigerer L, Fotsis T. Angiogenesis and angiogenesis inhibitors in pediatric diseases. Eur J Paediatr 1992; 151: 472-476.
25. Casey R, Li W. Factors controlling ocular angiogenesis. Am J Ophthalmol 1997; 124: 521-529.
26. Pluda JM, Feigal E, Yarchoan R. Noncytotoxic approaches to the treatment of HIV-associated Kaposi's sarcoma. Oncology 1993; 7: 25-33.
27. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-1200.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
29. Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G. Role of tumor necrosis factor alpha and platelet activating factor in neoangiogenesis induced by synovial fluid of patients with rheumatoid arthritis. Eur J Immunol 1996; 26: 1690-1694.
30. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994; 157: 291-299.
31. Boehm T, Folkman L, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
32. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 347-356.
33. Wiedner N. Measuring intratumoral microvessel density. In Angiogenesis: Models, Modulators and Clinical Applications, Maragoudakis M (ed). New York: Plenum Press, 1998; 61-74.
34. Wiedner N. Tumor vascularity: what does it tell us about the growth and spread of cancer? In Angiogenesis: Models, Modulators and Clinical Applications, Maragoudakis W (ed). New York: Plenum Press, 1998; 389-406.
35. Folkman J. Antiangiogenic therapy. In Cancer: Principles & Practice of Oncology. 5th edn, DeVita VT Jr, Hellman S, Rosenberg SA (eds). Philadelphia: Lippincott-Raven, 1997; 3075-3085.
36. Nyugen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993; 85: 241.
37. Li VW, Folkerth RD, Watanbe H, et al. Basic fibroblast growth factor in the cerebrospinal fluid of children with brain tumours correlation with microvessel count in the tumour. Lancet 1994; 344: 82-86.
38. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149-4156.
39. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
40. Rab ST, King SB III, Roubin GS, Carlin S, Hearn JA, Douglas JS Jr. Coronary aneurysms after stent placement: a suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J Am Coll Cardiol 1991; 18: 1524-1528.
41. Hanahan D. A flanking attack on cancer. Nature Med 1998; 4: 13-14.
42. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995; 203: 80-92.
43. Feucht M, Christ B, Wilting J. VEGF induces cardiovascular malformation and embryonic lethality. Am J Pathol 1997; 151: 1407-1416.
44. Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with CAI, thalidomide, TNP-470 and IL-12. Angiogenesis 1997; 1: 23-35.
45. Harris AL. Clinical trials of anti-vascular agent Group B streptococcus toxin (CM101). Angiogenesis 1997; 1: 36-37.
46. 3. Proc ASCO 1998; 17: 215a.
47. Erlichmann C, Adjei A, Alberts S, et al. Phase I study of Bay 12-9566 - a matrix metalloproteinase inhibitor. Proc ASCO 1998; 17: 217a.
48. Rosen LS, Kabbinavar F, Rosen P, Mulay M, Quigley S, Hannah AL. Phase I trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc ASCO 1998; 17: 218a.
49. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-218.
50. Gradishar WJ. An overview of clinical trials involving inhibitors of angiogenesis and their mechanisms of action. Invest New Drugs 1997; 15: 49-59.
51. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumour growth factor b1, platelet-derived endothelial cell growth factor, placental growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
52. Barton DPJ, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997; 3: 1579-1586.
53. Wakabayashi Y, Shomo T, Isono M, et al. Dual pathways to tubular morphogenesis of vascular endothelial cells by human glioma cells: vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8. Jpn J Cancer Res 1995; 86: 1189-1197.
54. DeVore RF, Hellerqvist CG, Wakefield GB, et al. Phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997; 3: 365-372.
55. Quinn TE, Thurman GB, Sundell AK, Zhang M, Hellerqvist CG. CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models. J Cancer Res Clin Oncol 1995; 121: 253-256.